DIA 
Patrik Pallagi
Founder & CEO
Seven years with the New York Academy of Sciences; BSc in Physics from the University of Toronto.
A smart insulin discovery endeavour
Insulin that
switches off
before glucose
goes low.
Rethinking the dose-limiting problem in insulin therapy.
A concept under investigation — not a tested therapy or product for patient use.
Contact DIA HEALTH ONE ↗A safer glucose response
CONCEPT
GLUCOSE LEVELTIME →
glucose responsesmart insulin
Responsive by design ↗
01 — DISCOVERY
01 / The need
Why we
need it.
Hypoglycemia is a recognized risk of insulin therapy.
It can constrain treatment.
That is the research challenge.
02 / The gap
Why is it
not fixed?
“Glucose-responsive insulin is an active research area. A 2024 preclinical study reported the glucose-sensitive insulin NNC2215. Read the Nature study ↗
A 2026 study reported an interaction between paracetamol glucuronide and NNC2215 in experimental measurements. We investigate the chemistry and computational evidence—not a clinical product or treatment recommendation. Read the ACS study ↗
03 / The approach
Compute.
Falsify.
Discover.
We compute the target, then falsify mechanisms analytically.
Each hypothesis is tested in days, not years.
TargetMechanismEvidence
04 / The team
Built by people who think in systems.
Our team combines company-building, scientific leadership, computational research, and engineering.
Andrii Shylenko
Chief Technology Officer
More than a decade of experience across industrial hardware, agentic AI, and machine learning.
